Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

Launched by AYUVIS RESEARCH, INC. · Feb 21, 2025

Keywords

ClinConnect Summary

This clinical trial is called a Phase 1 study for a new medication called AVR-48. The main goal is to understand how safe this medication is and how it behaves in the body (this is known as safety and pharmacokinetics). The study is divided into two parts: first, healthy adult volunteers will receive a single dose of AVR-48 or a placebo (a treatment that has no active ingredients) to see how they respond. If the single doses are deemed safe, the trial will move on to giving multiple doses of AVR-48 to evaluate its effects further.

To participate, individuals need to be healthy adults aged 18 to 55 who have a body mass index (BMI) between 18 and 32 and weigh between 50 and 100 kg. They should not be smokers or have any significant health issues that could affect their participation. Participants will be closely monitored throughout the study and will need to follow specific guidelines regarding medications and lifestyle. This trial is currently not recruiting participants, so if you're interested, you will need to wait until it opens for enrollment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of signed and dated informed consent form (ICF).
• • 2. Stated willingness to comply with all study procedures and availability for the duration of the study.
• • 3. Healthy adult male or female, aged 18 to 55, inclusive, at Screening.
• • 4. Continuous non smoker who has not used nicotine containing products (including e- vaping) for at least 3 months prior to the first dosing and throughout the study
• • 5. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening, and a minimum weight of at least 50.0 kg and a maximum weight of 100.0 kg at screening.
• • 6. Medically healthy with no clinically significant abnormalities in medical history, physical and neurologic examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
• • 7. If female of childbearing potential, must be consistently using an effective method of contraception from screening visit until 30 days after the last drug administration.
• • 8. If female and not of childbearing potential, must be either surgically sterile or post menopausal (i.e., more than 1 year since last menstrual period).
• • 9. A non-vasectomized, male subject must agree to use an effective method of birth control with female partners of childbearing potential during the study and to refrain from donating sperm for 90 days following dosing.
• • 10. No restrictions are required for a vasectomized male subject provided his vasectomy has been performed 4 months or more (and have official documentation) prior to Study Day 1. A subject who has been vasectomized less than 4 months prior to Study Day 1 or does not have official documentation of his vasectomy must follow the same restrictions as a non-vasectomized subject.
• Exclusion Criteria:
• • 1. Are mentally or legally incapacitated or have significant emotional problems at the time of the screening visit or expected during the conduct of the study in the opinion of the PI or designee.
• • 2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
• • 3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
• • 4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
• • 5. Has had surgery or any medical condition within 6 months prior to first dosing which may affect the distribution, metabolism, or elimination of the study drug, in the opinion of the PI or designee.
• • 6. Female subjects with a positive pregnancy test or who are lactating.
• • 7. Positive urine drug or alcohol results at screening or first check-in.
• • 8. Positive cotinine results at screening.
• • 9. Positive result at screening for tuberculosis (i.e., positive result for QuantiFERON TB-Gold).
• • 10. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
• 11. Unable to refrain from or anticipates the use of:
• • • Any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing and throughout the study. After first dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee. Hormone replacement therapy will be allowed.
• • 12. Donation or loss of 50 to 499 mL whole blood within 30 days or more than 499 mL whole blood within 56 days prior to the first dosing.
• • 13. Plasma donation within 14 days prior to the first dosing.
• • 14. Participation in another clinical study within 30 days prior to the first dosing. The 30 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
• • 15. Had a treatment with other investigational drug within 5 times the terminal elimination half-life (t1/2), if known (e.g., a marketed product) or within 30 days (if the t1/2 is unknown), whichever is longer, prior to Study Day 1 dosing.
• • 16. Evidence of Coronavirus Disease 2019 (COVID-19) infection.